Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Misleading Drug Ads Should Be Subject To Financial Penalties, AARP Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Congress should implement financial penalties for misleading drug ads, AARP Executive Director for State & National Initiatives Christopher Hansen said

You may also be interested in...



Manufacturers Respond To AARP Concerns On Pricing, But Decline To Take Pledge

Merck, GSK, Lilly and PhRMA will not voluntarily limit price increases as AARP requested. The tone of the responses, the seniors' group noted, has been cooperative. Several manufacturers suggested a meeting with AARP as the next step.

FDA Preclearance Of DTC Ads Included In Sen. Kennedy Draft Bill

Legislation would allow FDA to pre-approve ads from repeat offenders. TV ads would need to include full MedGuide information. Draft language also calls for ad disclaimers on new drugs for two years.

Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint

FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel